Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017

  • ID: 4311837
  • Report
  • 40 pages
  • Global Markets Direct
1 of 5
Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape.

Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder caused by the deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, Muscle spasms, Loss of head control, vomiting, fevers, irritability and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsant, muscle relaxer) and providing supportive care.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Globoid Cell Leukodystrophy (Krabbe Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
  1. Introduction
  2. Globoid Cell Leukodystrophy (Krabbe Disease) - Overview
  3. Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Globoid Cell Leukodystrophy (Krabbe Disease) - Companies Involved in Therapeutics Development
  15. Commence Bio Inc
  16. Kyorin Pharmaceutical Co Ltd
  17. Globoid Cell Leukodystrophy (Krabbe Disease) - Drug Profiles
  18. CMB-200 - Drug Profile
  19. Product Description
  20. Mechanism Of Action
  21. R&D Progress
  22. DUOC-01 - Drug Profile
  23. Product Description
  24. Mechanism Of Action
  25. R&D Progress
  26. ibudilast - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. MGTA-456 - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. RND-001 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. Stem Cell Therapy for Globoid Cell Leukodystrophy - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects
  43. Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products
  44. Globoid Cell Leukodystrophy (Krabbe Disease) - Product Development Milestones
  45. Featured News & Press Releases
  46. Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova’s MN-166 (ibudilast) for the Treatment of Krabbe Disease
  47. Jun 03, 2015: MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease
  48. Appendix
  49. Methodology
  50. Coverage
  51. Secondary Research
  52. Primary Research
  53. Expert Panel Validation
  54. Contact Us
  55. Disclaimer
List of Tables:
  1. Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Commence Bio Inc, H1
  11. Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1
  12. Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects, H1
  13. Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Targets, H1
  5. Number of Products by Stage and Targets, H1
  6. Number of Products by Mechanism of Actions, H1
  7. Number of Products by Stage and Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Molecule Types, H1
  11. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Commence Bio Inc
  • Kyorin Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll